(Press-News.org) DARIEN, IL – Eight finalists will compete in November for the first Sleep Medicine Disruptors Innovation Award from the American Academy of Sleep Medicine. The award competition is part of Sleep Medicine Disruptors 2025, which will be held in person in Austin, Texas, and livestreamed Friday and Saturday, Nov. 14 - 15.
An expert panel of nine AASM members reviewed and scored 23 entries according to their novelty, practicality, and potential to improve sleep health and sleep care by solving a significant and widespread problem. The eight entries with the highest overall scores received an invitation to give a pitch presentation in Austin.
Each finalist will compete for an award in one of two categories: diagnostics or therapeutics. The in-person and virtual attendees of Sleep Medicine Disruptors 2025 will select the two award winners.
Innovation Award Finalists | Diagnostics
Anatomic polysomnogram by Bairitone Health
Bairitone’s platform introduces the first anatomic polysomnogram: a non-invasive, skin-mounted sensor patch paired with an AI analysis platform that transforms routine sleep studies into a dynamic, anatomically resolved map of airway behavior during natural sleep (https://www.bairitone.com/).
DormoVision X by Dormotech
DormoVision X is an AI-powered, cloud-based platform that delivers true in-lab sleep study accuracy from the comfort of a patient’s home, providing real-time streaming of high-quality physiological data across multiple nights (https://www.dormotech.com/).
SleepBreath-PD by Health Intelligence Lab
SleepBreath-PD is an at-home and sleep-lab-ready platform that turns nocturnal breathing and sleep study data into an objective, repeatable digital biomarker for Parkinson’s disease and related neurodegenerative disorders (https://pd-breathing.csail.mit.edu/).
Onera Home PSG by Onera Technologies
The Onera home PSG type II system is FDA-cleared, and its patch-based technology enables comprehensive sleep diagnostics through four wireless, self-applied sensors that together capture a 15-channel, time-tested, and trusted sleep study dataset (https://www.onerahealth.com/).
Innovation Award Finalists | Therapeutics
AD109 by Apnimed
AD109 is a first-in-class oral pharmacologic treatment designed to improve oxygenation while patients sleep by targeting the neuromuscular pathway that maintains upper airway tone during sleep, addressing a fundamental mechanism of obstructive sleep apnea (https://apnimed.com/ad109/).
Modius Sleep by Neurovalens
Modius Sleep is an FDA-cleared, drug free, non-invasive headset that delivers low-level electrical impulses to the vestibular nerves through pads placed behind the ears when prescribed for use at home by adults who have chronic insomnia (https://neurovalens.com/modiussleep/).
Nidra by Noctrix Health
Powered by patented Tonic Motor Activation technology, Nidra is authorized by the FDA to treat restless legs syndrome by delivering high-frequency (4,000 Hz) stimulation to the peroneal nerve to activate afferent low-threshold proprioceptive fibers and induce activation of the tibialis anterior muscle (https://nidrarls.com/).
PST-1 for Sleep Apnea by WhisperSom
The WhisperSom PST-1 unifies diagnosis, treatment, and monitoring of sleep apnea into a single platform, combining a chest-worn sensor array (respiration, motion, heart rate, oximetry) with sleep-compatible earbuds to create a closed-loop solution for assessment and acoustic neuromodulation (https://whispersom.com/#intro).
Sleep Medicine Disruptors Program
This biennial event attracts clinicians, scientists, technology developers, start-up founders, venture capitalists, and other health care innovators. Speakers will explore technological innovation, artificial intelligence, and other disruptions that are poised to change the landscape of sleep health, patient care, and health care delivery. Keynote presentations will be delivered by Dr. Robert Pearl, former CEO of The Permanente Medical Group (Kaiser Permanente), and creativity strategist Natalie Nixon, who has a doctorate in design management.
In addition to nine featured lectures, the event will include the presentation of 25 abstracts during two poster sessions and oral presentation sessions. An exhibit hall will also feature products and services from leading companies in the industry.
Sleep Medicine Disruptors will be held at the Austin Marriott Downtown at 304 E. Cesar Chavez St. Registration information is available at aasm.org/disruptors.
###
About the American Academy of Sleep Medicine
Established in 1975, the AASM is a medical association that advances sleep care and enhances sleep health to improve lives. The AASM membership includes more than 9,500 physicians, scientists, and other health care professionals who help people who have sleep disorders. The AASM also accredits 2,300 sleep centers that are providing the highest quality of sleep care across the country (aasm.org).
END
Acute myeloid leukemia (AML), an aggressive and often fatal blood cancer, has long resisted a class of drugs called proteasome inhibitors, which work well in multiple myeloma. A new study by University of California San Diego researchers shows why: AML cells activate backup stress-response systems to stay alive when proteasomes are blocked. Proteasomes are cellular machines responsible for breaking down and recycling proteins, allowing cells to stay healthy. By combining proteasome inhibitors with a second drug that disables one of two backup survival pathways, the team was able to kill AML cells more effectively, reduce disease burden and extend ...
Researchers at the University of North Carolina have created microscopic soft robots shaped like flowers that can change shape and behavior in response to their surroundings, just like living organisms do. These tiny “DNA flowers” are made from special crystals formed by combining DNA and inorganic materials. They can reversibly fold and unfold in seconds, making them among the most dynamic materials ever developed on such a small scale.
Each flower’s DNA acts like a tiny computer program, telling it how to move and react to the world around ...
Melbourne researchers have discovered gender-affirming hormone therapy can alter body proteins to match a person’s gender identity, potentially affecting susceptibility to certain health conditions.
The research, led by Murdoch Children’s Research Institute (MCRI) and the University of Melbourne, found that sex-specific blood proteins in transgender women shifted significantly after six months of gender-affirming hormone therapy, resembling those of cisgender women.
MCRI Associate Professor Boris Novakovic said remarkably the therapy reduced ...
How do mammals manage to eat in situations that cause anxiety, step into exposed spaces, or slow down when anxiety drives them to keep moving? A new study pinpoints a leptin-sensitive circuit in the lateral hypothalamus that helps to overcome anxiety to perform essential behaviours such as exploring, feeding, and limiting maladaptive hyperactivity. Leptin is a hormone that acts in the brain, regulating energy balance, influencing appetite and eating behaviour. Leptin is sensed by neurons which have leptin receptors. Many of ...
In the right combinations and conditions, two-dimensional materials can host intriguing and potentially valuable quantum phases, like superconductivity and unique forms of magnetism. Why they occur, and how they can be controlled, is of considerable interest among physicists and engineers. Research published in Nature Physics reveals a previously hidden feature that could explain how and why enigmatic quantum phases emerge.
Using a new terahertz (THz) spectroscopic technique, the researchers revealed that tiny stacks of 2D materials, found in research labs around the world, can naturally form what are known as cavities. These cavities confine light and electrons into even ...
Bethesda, MD (Oct. 17, 2025) — The American Gastroenterological Association (AGA) today released a new clinical practice guideline on the surveillance of Barrett's esophagus, the only known precursor to esophageal cancer (adenocarcinoma), a highly lethal cancer whose incidence has risen substantially over recent decades. The guideline provides eight evidence-based recommendations and several key implementation statements to help clinicians monitor patients after a diagnosis of Barrett's esophagus, a condition associated with chronic ...
By the time patients start seeking care for multiple sclerosis (MS), the disease has already been damaging their brains for years. But until recently, scientists didn’t understand which brain cells were being targeted or when the injury began.
Now, by analyzing thousands of proteins found in the blood, scientists at UC San Francisco have created the clearest picture yet of when the disease attacks the myelin sheath that covers the nerve fibers. It shows that the immune system begins attacking ...
Some ancient marine organisms produced mysterious magnetic particles of unusually large size, which can now be found as fossils in marine sediments. An international team has succeeded in mapping the magnetic domains on one of such ‘giant magnetofossils’ using a sophisticated method at the Diamond X-ray source. Their analysis shows that these particles could have allowed these organisms to sense tiny variations in both the direction and intensity of the Earth’s magnetic field, enabling them to geolocate themselves and ...
Embargoed until 4 a.m. CT / 5 a.m. ET Monday, Oct. 20, 2025
DALLAS, Oct. 20, 2025 — About 9 in 10 U.S. adults have not heard of cardiovascular-kidney-metabolic (CKM) syndrome, a newly defined health condition affecting nearly 90% of adults that includes heart disease, kidney disease, diabetes and obesity, according to a new survey from the American Heart Association, a relentless force changing the future of health for everyone everywhere. However, many are interested in learning more about it.
Nearly 90% of U.S. adults have at least ...
PITTSBURGH, October 20, 2025 — Doctors and researchers at the University of Pittsburgh and UPMC have developed a new treatment for epilepsy patients who don’t respond to medication and aren’t candidates for surgery. Their approach, published today in Nature Communications, uses deep brain stimulation (DBS) that is tailored to each patient’s unique brain wiring.
Epilepsy affects more than 50 million people worldwide, and about a third of those do not respond to medication. For some, seizures are generated in parts of the brain that control essential functions – speech, movement or vision – that can’t be safely removed. Brain ...
